Drug Trial Radar · NCT05732103
A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
225
Planned (sponsor's estimate)
Start
Apr 25, 2023
Primary completion
Jun 2028
Study completion Feb 2029
Sponsor
- Lead sponsor
- Chordia Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Theradex
- First posted
- Feb 16, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this phase 1/2 multicenter, open-label, single-arm dose escalation and expansion study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic profile of CTX-712 in patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS), or MDS/MPN (including CMML). The phase 1 part of the study consists of sequential standard 3 + 3 dose escalation, where patients will receive ascending doses of CTX-712 to determine the recommended phase 2 dose (RP2D) for further clinical development. This is followed by initial expansion cohorts in AML and/or HR-MDS where patients will be treated with CTX-712 at the RP2D to gain further confidence in the selected dose level. Additional expansion cohorts may be initiated if considered necessary. After RP2D is determined, Drug-Drug-Interaction cohorts will be started. The phase 2 part of the study will commence after the RP2D has been identified and confirmed and will evaluate therapeutic activity in R/R AML or R/R HR-MDS, in addition to confirmation of the safety profile.
Conditions
- Acute Myeloid Leukemia
- Myelodysplastic Syndromes
Interventions
CTX-712Drug
CTX-712 will be provided as a 20 mg tablet for oral administration. Patients will take CTX-712 once or twice weekly, depending on their dose level assignment, during each 28-day cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Frequency of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) related to CTX-712.Time frame: Adverse events are collected from time of informed consent through 28 days after last dose of CTX-712.
- Phase 1: The maximum tolerated dose MTD.Time frame: Dose-limiting toxicities are collected during the first treatment cycle (28 days).
- Phase 2: Complete remission rate, defined as the proportion of patients who achieve complete remission.Time frame: Measured from date of first dose to 28 days after last dose of CTX-712.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Mayo Clinic Arizona
Phoenix, Arizona · Recruiting
Mayo Clinic Florida
Jacksonville, Florida · Recruiting
Northwestern University
Chicago, Illinois · Recruiting
Mayo Clinic Comprehensive Cancer Center
Rochester, Minnesota · Recruiting
The University of Rochester
Rochester, New York · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Virginia
Charlottesville, Virginia · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.